益中生血胶囊治疗肿瘤相关性贫血的临床观察

《益中生血胶囊治疗肿瘤相关性贫血的临床观察》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、益中生血胶囊治疗肿瘤相关性贫血的临床观察侯丽】，倪磊2,陈信义I,陆鸿飞I(1.北京屮医药大学东直门医院血液肿瘤科，北京100700；2.北京屮医药大学，北京100700)摘要：目的：观察益中生血胶囊治疗肿瘤相关性贫血的临床疗效。方法：根据临床研究方案，共收集有效病例46例，根据性别、原发部位、TNM分期，进行随机化分组，试验组22例，对照组24例。对照组根据具体病情，采用常规必耍辅助治疗；试验组在对照组治疗方案基础上，口服益中生血胶囊3粒/次，3次/日，连续用药4周。结果：经过4周治疗后，对照组H

2、b(血红蛋白)较治疗前显著下降(P<().()5)，试验组Hb较治疗前显著上升(P<().()5),治疗前试验组Hb明显低于对照组(PV0.05),治疗后试验组Hb与对照组比较，无统计学意义(P>0.05)o结论：益中生血胶囊有对抗或纠正Hb下降趋势的作用,对肿瘤相关性贫血有治疗作用。关键词：益中生血胶囊；肿瘤相关性贫血；临床观察中图分类号：R733.71文献标识码：AClinicalObservationoftheEffectofBenefitingZhongjiaoandProducingBlo

3、odCapsuleonCancer-relatedAnemiaHOULii,NILei2,CHENXinyii,LUHongfeii(1.DepartmentofOncologyandHematology,DongzhimenHospitalAffiliatedtoBeijingUniversityofChineseMedicine,Beijing100700;2.BeijingUniversityofChineseMedicine,Beijing100700)Abstract:Objective：

4、ToobservetheclinicaleffectofBenefitingZhongjiaoandProducingBloodCapsuleoncancer-relatedanemia・Methods：Trackingtheclinicalresearchplan,Thecollected46casesweredividedinto2groupsinrandombasedonsex,primaryorgansandTNMstage・Thetrialgroupcontained22casesandt

5、hecontrolgroupdid24cases.Thecontrolgrouptookadjuvanttreatmentaccordingtotheconditionofthedisease.Besideofthecontrolgroup'streatmentprotocols,thetrialgrouptooktheBenefitingZhongjiaoandProducingBloodCapsuletreetablets3timesdailyfor4weeks・Results:After4we

6、ekstreatment,averageHblevelofthecontrolgroupdecreasedevidently(P<0.05)whilethetrialgroupincreasedevidently(P<0.05).Beforethetreatment,averageHblevelofthetrialgroupwasapparentlyfarlowerthanthatofthecontrolgroup(P<0.05);however,afterthetreatment,theirdif

7、ferentiationwasnotevidentinstatistics(P>0.05).Conclusion：ThisshowsthatBenefitingZhongjiaoandProducingBloodCapsulecanresistorevenreversethetrendofHbdecrease,whichcanpreventcancer-relatedanemiafromgettingworseandenhaneeshort-termclinicaleffect.Keywords:B

8、enefitingZhongjiaoandProducingBloodCapsule;cancer-relatedanemia;Clinicalobservation0引言肿瘤相关性贫血近年来受到国内外医学界的普遍巫视，其不仅严IE影响了肿瘤治疗的临床疗效，也可导致患者生活质量下降。肿瘤相关性贫血是多种因素相互作用的结果，H前尚不能以某一单因素予以说明。输血和应用重组人红细胞牛成素(erythropoietin,EPO)是治疗肿瘤相关性贫血的主要治疗手段，然而疗效维持